New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AKR;MCD;MPEL;SYT;RHHBY;TSM;DST;AET;ATHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
March 23, 2015
10:01 EDTMPELOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allied World (AWH) initiated with a Market Perform at Keefe Bruyette... Capnia (CAPN) initiated with a Buy at Maxim... Catamaran (CTRX) initiated with a Buy at Mizuho... CyberArk (CYBR) initiated with a Buy at BofA/Merrill... Inotek Pharmaceuticals (ITEK) initiated with a Buy at Canaccord... Kinder Morgan (KMI) initiated with a Buy at Argus... MGM China (MCHVF) initiated with a Market Perform at Bernstein... Maxim Integrated (MXIM) initiated with a Buy at Summit Research... Melco Crown (MPEL) initiated with an Outperform at Bernstein... Microsemi (MSCC) initiated with an Outperform at BMO Capital... Sands China (SCHYY) initiated with an Outperform at Bernstein... Tetraphase (TTPH) initiated with a Buy at Nomura... Vista Outdoor (VSTO) initiated with a Sector Weight at KeyBanc... Wynn Macau (WYNMF) initiated with a Market Perform at Bernstein.
08:46 EDTRHHBYEli Lilly price target raised to $85 from $78 at Cowen
Subscribe for More Information
07:39 EDTMPELMelco Crown initiated with an Outperform at Bernstein
Target $32.
06:32 EDTRHHBYFoundation Medicine announces board changes in connection to Roche transaction
Foundation Medicine (FMI) announced proposed changes to its board in connection with its pending strategic collaboration with Roche (RHHBY). Under the terms of the agreement with Roche, Foundation Medicine’s board will increase to nine directors upon the closing of the transaction, including three board designees selected by Roche. The pending transaction with Roche remains subject to the satisfaction of certain closing conditions, including the successful completion of the tender offer commenced by Roche on February 2, 2015 and the approval of certain matters at the special meeting of Foundation Medicine stockholders to be held on April 2, 2015. The closing is expected to occur in the second quarter of 2015.
March 22, 2015
16:22 EDTSYTChina looks to develop seed program to fend off foreign competition, WSJ says
Subscribe for More Information
March 20, 2015
16:00 EDTMCDOptions Update; March 20, 2015
Subscribe for More Information
11:33 EDTRHHBYFly Review: Analysts correctly predict jump in Biogen shares
The shares of Biogen (BIIB) are rallying after the company reported results for a Phase 1b study of its Alzheimer's drug, BIIB-037. On March 18, as reported on that day by The Fly, RBC Capital predicted that the stock would rise after the results were published. A number of other firms were also upbeat on the stock ahead of the data release. WHAT'S NEW: Earlier this morning Biogen announced that the three milligram, six milligram, and ten milligram dose versions of its Alzheimer's treatment, aducanumab, had reduced the amount of amyloid plaque in the brains of Alzheimer's patients taking the drug by statistically significant amounts compared with those taking placebos. Beta amyloid is a protein that produces plaque in the brain. Scientists suspect that plaques in the brain are a cause of Alzheimer's. The cognitive decline of patients taking BIIB-037 was also significantly less than that of patients who were taking placebos, the company reported. PRE-EVENT CALLS: RBC Capital analyst Michael Yee predicted earlier this week in a note to investors that Biogen would report strong data for BIIB-037 and the stock should "work higher" after the data is unveiled. Alzheimer's patients taking the high dose of Biogen's BIIB-037 drug should exhibit a stabilization of cognition levels, Yee stated. Conversely, the cognition levels of patients taking the placebo should drop slightly, the analyst predicted. On March 13, in a note summarized by The Fly on that day, JPMorgan recommended buying Biogen shares ahead of the data release. Investors still incorporated a low probability of success for the drug, and the stock could rise further, the firm wrote. On March 19, in a note also published by The Fly, Credit Suisse wrote that Biogen's multiple could rise if the data on BIIB-037 was positive. It raised its price target on the name to $500 from $400. ANALYST REACTION: This morning, Barclays raised Biogen's price target to $500 from $435 following the company's report of "impressive" full results from the Alzheimer's study. Piper Jaffray analyst Joshua Schimmer also raised his price target for Biogen shares to $500 this morning, calling today’s BIIB-037 results "robust and impressive." Schimmer believes the trial showed a "consistent and dramatic" dose effect on both radiographic and clinical disease features and thinks the side effects "pale in comparison" to the drug’s efficacy. OTHERS TO WATCH: Eli Lilly (LLY) and Roche (RHHBY) are also currently developing similar Alzheimer's treatments. PRICE ACTION: In late morning trading, Biogen rose 7% to $464. The stock is up about 9% since Wednesday. Eli Lilly shares are up 1.6% to $75.40 this morning, while Roche rose 2.2% to $35. Reference Link
09:01 EDTRHHBYEli Lilly up 2% to $75.75 in pre-market trading
Subscribe for More Information
08:18 EDTAETLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
05:58 EDTTSMTaiwan chipmakers unaffected by water shortages, DigiTimes reports
Subscribe for More Information
March 19, 2015
16:14 EDTRHHBYProthena report positive results from Phase 1 study of PRX002
Subscribe for More Information
13:00 EDTMPELCasino operators jump after analyst starts with Buy ratings
Subscribe for More Information
10:02 EDTMPELOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:02 EDTAETOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:20 EDTAETAetna upgraded at Sterne Agee
As noted earlier, Sterne Agee upgraded Aetna to Buy from Neutral. The firm says that the company is the best-positioned name within the large-cap health plan space , a defensive sector that has little exposure to Europe and reasonable growth prospects, according to the firm.
07:02 EDTRHHBYSigma-Aldrich signs exclusive distribution agreement with Roche
Subscribe for More Information
06:19 EDTAETAetna upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
06:15 EDTATHNathenahealth coverage transferred with an Outperform at RW Baird
Subscribe for More Information
March 18, 2015
16:23 EDTMPELMelco Crown initiated with a Buy at Brean Capital
Subscribe for More Information
12:48 EDTRHHBYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use